Fixed-combination therapies in hypertension management: Focus on enalapril/lercanidipine

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 2, 2009, Pages 115-123

  Tocci, Giuliano ^a   Palano, Francesca ^a   Pagannone, Erika ^a   Chin, Diana ^a   Ferrucci, Andrea ^a   Volpe, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiovascular risk; Enalapril; Fixed combination therapy; Hypertension; Lercanidipine

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM PLUS ENALAPRIL MALEATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE PLUS FELODIPINE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; ENALAPRIL PLUS LERCANIDIPINE; FELODIPINE; FELODIPINE PLUS RAMIPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LERCANIDIPINE; NIFEDIPINE; NITRENDIPINE; PLACEBO; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANKLE EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRESCRIPTION; RENAL PROTECTION; REVIEW; SIDE EFFECT; VASODILATATION; VERTIGO; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; PATHOPHYSIOLOGY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DIHYDROPYRIDINES; DRUG COMBINATIONS; ENALAPRIL; HUMANS; HYPERTENSION; MEDICATION ADHERENCE;

EID: 64749094680     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.2.115     Document Type: Review

References (57)

1. Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25(9), 1751-1762 (2007).
2. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
3. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J. Hum. Hypertens. 18(3), 139-185 (2004).
4. Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43(1), 10-17 (2004).
5. Boersma E, Keil U, De Bacquer D et al. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J. Hypertens. 21(10), 1831-1840 (2003).
6. Volpe M, Tocci G, Trimarco B et al. Blood pressure control in Italy: results of recent surveys on hypertension. J. Hypertens. 25(7), 1491-1498 (2007).
7. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438), 937-952 (2004).
8. de Simone G, Devereux RB, Chinali M et al. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: The Strong Heart Study. Nutr. Metab. Cardiovasc. Dis. DOI:10.1016/ j.numecd.2008.04.001 (2008).
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 145-153 (2000).
10. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-loweriag regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358(9287), 1033-1041 (2001).
11. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981-2997 (2002).
12. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (9311), 1004-1010 (2002).
13. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290(21), 2805-2816 (2003).
14. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363(9426), 2022-2031 (2004).
15. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895-906 (2005).
16. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J. Hypertens. 23(12), 2157-2172 (2005).
17. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369(9571), 1431-1439 (2007).
18. Jamerson K, Bakris GL, Dahlof B et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 16(2), 80-86 (2007).
19. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens. 21(6), 1055-1076 (2003).
20. Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336(7653), 1121-1123 (2008).
21. Verdecchia P, Reboldi G, Angeli F et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46(2), 386-392 (2005).
22. Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med. 165(12), 1410-1419 (2005).
23. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J. Hypertens. 20(8), 1461-1464 (2002).
24. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J. Hypertens. 26(7), 1477-1486 (2008).
25. Mancia G, Omboni S, Grassi G. Combination treatment in hypertension: the VeraTran Study. Am J. Hypertens. 10(7 Pt 2), S153-S158 (1997).
26. Volpe M, Machado E. Treatment priorities and current prescribing patterns in hypertension: results of GRASP, an international physician survey. Curr. Med. Res. Opin. 20(7), 1151-1160 (2004).
27. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404), 1427 (2003).
28. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med. 358(6), 580-591 (2008).
29. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med. 348(5), 383-393 (2003).
30. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370(9590), 829-840 (2007).
31. Struijker-Boudier HA, Ambrosioni E, Holzgreve H et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? Int. J. Clin. Pract. 61(9), 1592-1602 (2007).
32. Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance and fixed-dose combination therapy. Curr. Hypertens. Rep. 9(3), 184-189 (2007).
33. Messerli FH, Chander K. Cardiac effects of combination therapy in hypertension. J. Cardiovasc. Pharmacol. 35(Suppl. 3), S17-S22 (2000).
34. Messerli FH, Grossman E, Michalewicz L. Combination therapy and target organ protection in hypertension and diabetes mellitus. Am J. Hypertens. 10(9 Pt 2), 198S-201S (1997).
35. Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 67(9), 1309-1327 (2007).
36. Ruschitzka FT, Noll G, Luscher TF. Combination of ACE inhibitors and calcium antagonists: a logical approach. J. Cardiovasc. Pharmacol. 31(Suppl. 2), S5-S16 (1998).
37. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J. Hypertens. 14(9 Pt 1), 963-968 (2001).
38. Faulkner MA, Hilleman DE. Amlodipine/benazepril: fixed dose combination therapy for hypertension. Expert Opin. Pharmacother. 2(1), 165-178 (2001).
39. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am. J. Cardiol. 86(11), 1182-1187 (2000).
40. Siddiqui MA, Plosker GL. Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension. Drugs 64(10), 1135-1148 (2004).
41. Rachmani R, Levi Z, Zadok BS, Ravid M. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin. Pharmacol. Ther. 72(3), 302-307 (2002).
42. Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabetes, ipertensione, albuminuria, lercanidipina). Diabetes Nutr. Metab. 17(5), 259-266 (2004).
43. Borghi C. Lercanidipine in hypertension. Vasc. Health Risk Manag. 1(3), 173-182 (2005).
44. McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 60(5), 1123-1140 (2000).
45. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 63(22), 2449-2472 (2003).
46. Beckey C, Lundy A, Lutfi N. Lercanidipine in the treatment of hypertension. Ann. Pharmacother. 41(3), 465-473 (2007).
47. Schillaci G, Verdecchia P, Reboldi G, Pede S, Porcellati C. Subdinical left ventricular dysfunction in systemic hypertension and the role of 24-hour blood pressure. Am. J. Cardiol. 86(5), 509-513 (2000).
48. Martinez ML, Castro MM, Rizzi E et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur. J. Pharmacol. 591(1-3), 224-230 (2008).
49. Todd PA, Goa KL. Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43(3), 346-381 (1992).
50. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 18(3), 588-599 (1998).
51. Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/ enalapril. Drugs 67(1), 95-108 (2007).
52. Puig JG, Calvo C, Luurila O et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J. Hum. Hypertens. 21(12), 917-924 (2007).
53. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J. Hypertens. 24(1), 185-192 (2006).
54. Borghi C, Prandin MG, Dormi A, Ambrosioni E. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press. 12(Suppl. 1), 14-21 (2003).
55. Barrios V, Escobar C, de la Figuera M et al. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc. Ther. 26(1), 2-9 (2008).
56. Barrios V, Escobar C, de la Figuera M et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int. J. Clin. Pract. 62(5), 723-728 (2008).
57. Barrios V, Escobar C, Navarro A, Barrios L, Navarro-Cid J, Calderon A. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA study. Int. J. Clin. Pract. 60(11), 1364-1370 (2006).